Investors are overlooking healthcare stocks and should consider these top picks, says JPMorgan
JPMorgan says investors are overlooking U.S. healthcare stocks and expects sector net income to rise 22% in 2027 after a 1% decline in 2026. The bank cites favorable valuations and predicted earnings growth as a key driver for S&P 500 profits. It names Eli Lilly (LLY), Gilead (GILD), AbbVie (ABBV), Danaher (DHR), and Thermo Fisher (TMO) as top picks, noting risks like a 2028 patent cliff.
How this was made
The 30-second read
Why it matters
The article is a sector rotation and valuation thesis with named stock picks. It does not provide new company-specific catalysts, so trading impact is likely sentiment-driven rather than fundamental repricing.
Market read
A bullish healthcare sector narrative with a named-picks list, but no fresh earnings, trial, or deal details for the individual stocks.
What to watch
The note flags multiple policy uncertainties (Medicaid funding debates, tariffs, reimbursement changes) but does not quantify how they map to each named company’s earnings sensitivity.
Background
JPMorgan argues investors have rotated toward AI and overlooked healthcare, which it says trades at a meaningful discount despite an earnings growth rebound expected in 2027.
Ticker impact
JPMorgan names Eli Lilly as a top biopharma pick, citing improving fundamentals and attractive healthcare valuations.
Mild positive bias for near-term sentiment; limited incremental impact without company-specific new data.
The only disclosed fact tied to LLY is JPMorgan’s recommendation, with no earnings, trial, guidance, or deal details.
JPMorgan lists Gilead Sciences among its top biopharmaceutical picks, tied to expected sector earnings rebound.
Low-to-moderate positive drift if investors rotate into healthcare, but likely limited immediate repricing.
The article does not disclose any Gilead-specific event; it is a sector valuation and outlook argument.
AbbVie is included by JPMorgan as a top healthcare pick, with the thesis anchored to improving sector earnings and valuation discounts.
Gradual positive sentiment impact; unlikely to drive a sharp move absent new AbbVie catalysts.
No patent, trial, regulatory, or financial update for AbbVie is provided beyond being named in the list.
Danaher (DHR) is cited by JPMorgan as a top pick in medical technology/life science tools on improving fundamentals and valuations.
Small positive tilt; more of a rotation signal than a catalyst.
The text provides no DHR-specific contract, guidance, or product event.
Thermo Fisher Scientific (TMO) is named by JPMorgan as a top life science tools pick, linked to the sector’s expected earnings growth rebound.
Limited immediate impact; could help maintain bid if the market buys the sector discount narrative.
The article’s newest facts are sector-level (earnings growth reversal, valuation discount, policy risks), not TMO-specific.
Market effects
Reinforces a potential rotation trade into healthcare, citing expected 2027 earnings growth of over 22% and a persistent valuation discount.
Primarily US-focused (U.S. healthcare sector lag and S&P 500 profit contribution framing).
Limited direct global linkage; the thesis is driven by US policy and US sector earnings expectations.
Counterpoint
Healthcare’s discount may reflect structural risks (drug pricing reform, reimbursement constraints, and the 2028 patent cliff), so a valuation-based call could understate downside if policy tightens further.
Key entities
- financial_institutionJPMorgan
Investment bank whose strategists issued the healthcare sector outlook and named stock picks.
- companyEli Lilly
Biopharmaceutical pick cited by JPMorgan (LLY).
- companyGilead Sciences
Biopharmaceutical pick cited by JPMorgan (GILD).
- companyAbbVie
Biopharmaceutical pick cited by JPMorgan (ABBV).
- companyDanaher
Medical technology/life science tools pick cited by JPMorgan (DHR).
